EP3810110A4 - Kombination aus fingolimod und amantadin - Google Patents

Kombination aus fingolimod und amantadin Download PDF

Info

Publication number
EP3810110A4
EP3810110A4 EP19823241.5A EP19823241A EP3810110A4 EP 3810110 A4 EP3810110 A4 EP 3810110A4 EP 19823241 A EP19823241 A EP 19823241A EP 3810110 A4 EP3810110 A4 EP 3810110A4
Authority
EP
European Patent Office
Prior art keywords
amantadine
combination including
fingolimod
including fingolimod
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19823241.5A
Other languages
English (en)
French (fr)
Other versions
EP3810110A2 (de
Inventor
Ali Turkyilmaz
Merve PEKER
Emine TUNCAY
Erkin Ozturk
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3810110A2 publication Critical patent/EP3810110A2/de
Publication of EP3810110A4 publication Critical patent/EP3810110A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19823241.5A 2018-06-21 2019-06-20 Kombination aus fingolimod und amantadin Withdrawn EP3810110A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201808819 2018-06-21
PCT/TR2019/050477 WO2019245513A2 (en) 2018-06-21 2019-06-20 A combination comprising fingolimod and amantadine

Publications (2)

Publication Number Publication Date
EP3810110A2 EP3810110A2 (de) 2021-04-28
EP3810110A4 true EP3810110A4 (de) 2022-03-16

Family

ID=68983747

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19823241.5A Withdrawn EP3810110A4 (de) 2018-06-21 2019-06-20 Kombination aus fingolimod und amantadin

Country Status (2)

Country Link
EP (1) EP3810110A4 (de)
WO (1) WO2019245513A2 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064997A1 (en) * 2014-10-22 2016-04-28 The Regents Of The University Of California Compositions and methods for treating fatigue and depression
US20160228388A1 (en) 2014-11-04 2016-08-11 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALICE LARONI ET AL: "Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 14, no. 1, 1 April 2014 (2014-04-01), pages 65, XP021184467, ISSN: 1471-2377, DOI: 10.1186/1471-2377-14-65 *
JEFFREY A COHEN ET AL: "MULTIPLE SCLEROSIS MSJ JOURNAL Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo- controlled, phase 2 trial", 1 January 2018 (2018-01-01), XP055472325, Retrieved from the Internet <URL:http://journals.sagepub.com/doi/pdf/10.1177/1352458518754716> [retrieved on 20180503] *
LIMMROTH V ET AL: "Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study", BMC NEUROLOGY 20170118 BIOMED CENTRAL LTD. GBR, vol. 17, no. 1, 18 January 2017 (2017-01-18), XP009533336, ISSN: 1471-2377 *
See also references of WO2019245513A2 *

Also Published As

Publication number Publication date
WO2019245513A3 (en) 2020-03-19
EP3810110A2 (de) 2021-04-28
WO2019245513A2 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
EP3735685A4 (de) Anzeigetafel
EP3797853A4 (de) Luftreiniger
EP3750149C0 (de) Anzeigetafel
EP3798719A4 (de) Anzeigetafel
EP3661363A4 (de) Mikrobielle impfmittelzusammensetzungen und -verfahren
EP3518708A4 (de) Nachgiebige sitzstruktur
EP3816518A4 (de) Luftreiniger
EP3755296A4 (de) Sitzstütze
EP3982415A4 (de) Anzeigetafel
EP3856390A4 (de) Luftreiniger
JP2020012785A5 (de)
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
EP3794015A4 (de) Aktivierungsmittel
EP3886698A4 (de) Atmungsanzeiger
EP3897798A4 (de) Befeuchterbehälter
EP3742509A4 (de) Anzeigetafel
EP3634226A4 (de) Indikatorbestimmung
EP3741987A4 (de) Luftreiniger
EP3810110A4 (de) Kombination aus fingolimod und amantadin
EP3651199A4 (de) Anzeigetafel
EP3589695A4 (de) Feuchtigkeitshärtende omniphobe beschichtungen
EP3890849A4 (de) Übungsmatte
MA51199A (fr) Agents d&#39;imagerie
EP3796813A4 (de) Sitzmöbel
EP3747955A4 (de) Acetylpolyaminnachweismittel

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201225

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220215

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20220209BHEP

Ipc: A61K 31/137 20060101ALI20220209BHEP

Ipc: A61K 31/13 20060101AFI20220209BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220915